- The 8 States Most Likely to Legalize Marijuana Next
- Dow 18,000: Why This Market Rally May Never Happen Again
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
- BlackBerry Classic Review: A Bold Update for CrackBerry Fans
But if the rally cools, some of these ideas may move still lower.
The newly appreciated stock will have to contend with the industry's inventory issues.
The e-reader has only a fringe following, but it could slow the bookseller's rebound.
The company leaves its Revlimid target set too high, setting it up for disappointment.